Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as C$0.66 and last traded at C$0.67, with a volume of 125156 shares changing hands. The stock had previously closed at C$0.69.

Oncolytics Biotech Trading Down 5.8%

The company has a fifty day moving average price of C$0.79 and a 200-day moving average price of C$1.08. The firm has a market capitalization of C$50.10 million, a price-to-earnings ratio of -1.81 and a beta of 1.35. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.